GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » 3-Year RORE %

PLSH (Panacea Life Sciences Holdings) 3-Year RORE % : -18.17% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Panacea Life Sciences Holdings's 3-Year RORE % for the quarter that ended in Sep. 2024 was -18.17%.

The industry rank for Panacea Life Sciences Holdings's 3-Year RORE % or its related term are showing as below:

PLSH's 3-Year RORE % is ranked worse than
64.52% of 978 companies
in the Drug Manufacturers industry
Industry Median: -1.65 vs PLSH: -18.17

Panacea Life Sciences Holdings 3-Year RORE % Historical Data

The historical data trend for Panacea Life Sciences Holdings's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings 3-Year RORE % Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
3-Year RORE %
- - - 13.44

Panacea Life Sciences Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.86 13.44 -1.61 -12.46 -18.17

Competitive Comparison of Panacea Life Sciences Holdings's 3-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Life Sciences Holdings's 3-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's 3-Year RORE % falls into.



Panacea Life Sciences Holdings 3-Year RORE % Calculation

Panacea Life Sciences Holdings's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.35--0.612 )/( -1.442-0 )
=0.262/-1.442
=-18.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.


Panacea Life Sciences Holdings  (OTCPK:PLSH) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Panacea Life Sciences Holdings 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Life Sciences Holdings Business Description

Traded in Other Exchanges
N/A
Address
5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. Its products are CBD Softgels, CBD Tablets, CBD Topicals, CBD Skin Care, CBD Tinctures, CBD Edibles, CBD Patches, CBD Pets, and PPE.
Executives
Leslie Buttorff director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER 16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger director 5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman officer: CONTROLLER & PRIN ACTNG OFCR 16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc. 10 percent owner 8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner 10 percent owner 65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert director 170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du officer: Chief Growth Officer 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis director 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky director, 10 percent owner 332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz director 332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson officer: Chief Strategy Officer 80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi officer: President 510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert director, officer: Executive Chairman 36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price director 4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval director NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019

Panacea Life Sciences Holdings Headlines

From GuruFocus

Panacea Announces Letter of Intent to Acquire N7 Enterprises, Inc.

By Stock market mentor Stock market mentor 01-23-2023